Results 71 to 80 of about 1,425,061 (397)

Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital

World Journal of Surgical Oncology, 2018
Background To investigate the importance of adjuvant chemotherapy in locally advanced rectal cancer (≥ cT3 or N+) staged ypT0–2 ypN0 on final histological work-up after neoadjuvant chemoradiation and radical resection.
Christian Galata, Kirsten Merx, Sabine Mai, Timo Gaiser, Frederik Wenz, Stefan Post, Peter Kienle, Ralf-Dieter Hofheinz, Karoline Horisberger   +8 more
doaj   +1 more source

Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer

Clinical Cancer Research, 2019
Purpose: For stage II colon cancer, the efficacy of postoperative adjuvant chemotherapy remains controversial. It is well known that tumor-associated macrophages (TAMs) are important in tumor progression.
Q. Feng, W. Chang, Y. Mao, G. He, P. Zheng, W. Tang, Ye Wei, L. Ren, Dexiang Zhu, M. Ji, Yongjiu Tu, X. Qin, Jianming Xu   +12 more
semanticscholar   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Lipids in Health and Disease, 2021
Background Cancer patients often exhibit chemotherapy-associated changes in serum lipid profiles, however, their prognostic value before and after adjuvant chemotherapy on survival among non-small-cell lung cancer (NSCLC) patients is unknown.
Fan Luo, Kang-mei Zeng, Jia-xin Cao, Ting Zhou, Su-xia Lin, Wen-juan Ma, Yun-peng Yang, Zhong-han Zhang, Fei-teng Lu, Yan Huang, Hong-yun Zhao, Li Zhang   +11 more
doaj   +1 more source

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

JAMA Oncology, 2019
Key Points Question Can a shortened course of adjuvant oxaliplatin-based chemotherapy reduce peripheral sensory neuropathy (PSN) without compromising efficacy in patients with stage III colon cancer?
T. Yoshino, T. Yamanaka, E. Oki, M. Kotaka, D. Manaka, T. Eto, J. Hasegawa, A. Takagane, Masato Nakamura, Takeshi Kato, Y. Munemoto, S. Takeuchi, H. Bando, H. Taniguchi, M. Gamoh, M. Shiozawa, T. Mizushima, S. Saji, Y. Maehara, A. Ohtsu, M. Mori   +20 more
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Making sense of adjuvant chemotherapy in colorectal cancer.

Journal of Gastrointestinal Oncology, 2019
Surgical resection is the only curative treatment for locoregional colon cancer. The goal of adjuvant chemotherapy is to eradicate micro-metastatic disease and improve survival. This has been most clearly demonstrated in stage III (node-positive) disease,
Gloria Chan, C. Chee
semanticscholar   +1 more source

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]

, 2013
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O, Brufsky, Adam M, Kaufman, Peter A, Mayer, Musa, Rugo, Hope S, Tripathy, Debu, Ulcickas Yood, Marianne, Yardley, Denise A, Yoo, Bongin   +8 more
core   +1 more source

A Retrospective Analysis using Deep-Learning Models for Prediction of Survival Outcome and Benefit of Adjuvant Chemotherapy in Stage II/III Colorectal Cancer [PDF]

, 2021
Xingyu Li, Jitendra Jonnagaddala, Shuhua Yang, Hong Zhang, Xu Steven Xu   +4 more
openalex   +1 more source